- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01439607
Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease (MGMC)
Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells, Macrophages and Plasma Cell Biology in Gaucher Disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gaucher disease is an inherited autosomal recessive lysosomal storage disorder caused by the defective activity of the glucocerebrosidase, leading to accumulation of glucocerebroside particularly in cells of the macrophage lineage. Clinical manifestations associate hematological, neurological and bone disorders.
In this project, the investigators aimed to study the cellular and molecular mechanisms governing the biology of various cell populations of the bone marrow and blood in these patients in order to define their potential role in the physiopathology of the disease. The main research topics the investigators plan will then be focused on characterization and functional analysis of hematopoietic stem cells, mesenchymal stem cells (with a special focus on osteogenic differentiation), macrophages and osteoclastic differentiation, B lymphocytes and plasma cells.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- Bertrand Arnulf
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age > 18 years
- Gaucher disease
- clinical examination written consent
Exclusion Criteria:
- pregnancy
- HIV seropositive
- contraindication to bone marrow sampling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Bone marrow and blood sampling
|
Bone marrow and blood sampling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
stem cells
Time Frame: day 1
|
day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bertrabd Arnulf, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
Other Study ID Numbers
- P081102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gaucher Disease
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
CANbridge (Suzhou) Bio-pharma Co., Ltd.RecruitingGaucher Disease, Type 1 | Gaucher Disease, Type 3China
-
Cambridge University Hospitals NHS Foundation TrustMedical Research Council; National Institute for Health Research, United KingdomRecruitingGaucher Disease, Type III | Gaucher Disease, Type IUnited Kingdom
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
AVROBIOWithdrawn
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Spur TherapeuticsCompletedGaucher Disease, Type 1Israel, United States, United Kingdom, Brazil, Germany, Spain
Clinical Trials on Bone marrow and blood sampling
-
Universitair Ziekenhuis BrusselStichting tegen KankerCompleted
-
Institut Paoli-CalmettesCompleted
-
University Hospital, Strasbourg, FranceUnknown
-
Stanford UniversityCompletedLeukemia, Lymphocytic, AcuteUnited States
-
Institut CurieActive, not recruitingLeukemia | Osteosarcoma | Neuroblastoma | Rhabdomyosarcoma | Central Nervous System Tumor | Ewing Sarcoma Family of TumorsFrance
-
University Hospital, ToulouseNot yet recruiting
-
Rennes University HospitalCompleted
-
University Hospital, ToulouseRecruiting
-
Hospices Civils de LyonCompleted
-
Ankara Children's Health and Diseases Hematology...Turkish Society of HematologyUnknownPre B ALL | Regulatory T Cell